San Francisco, California, April 26, 2018: The rising prevalence of acne vulgaris as skin diseases in worldwide population, especially among late adolescents, combined with substantial burden disease has on patients is a key factor driving the demand for treatments. The focus on successful management of the disease by a combination of topical and systemic drugs helps in expanding the available therapeutic options, thereby accentuating the market. A new report penned by TMR Research, titled, “Acne Vulgaris Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025”, offers insights into such trends and more and evaluates their impact on the growth dynamics over the forecast period of 2017 to 2025.
The market is significantly benefitting from the rising demand for novel therapeutics that can target a wide range of bacterial agents and have anti-inflammatory effect on the acne lesions. In this regard, relentless research in recent years to develop targeted therapeutic modalities have expanded the treatment regime for the disease.
The growing affordability of acne vulgaris treatments in global patient population is a notable factor accentuating the market. The advent of comprehensive treatment such as gels that can target multiple pathogenic factors for acne vulgaris and are helpful in reducing painful lesions is boosting the market.
Get Sample Copy of this Report @
Several pharmaceutical companies are holding back on spending large sums in research and development of therapeutics for acne vulgaris owing to uncertain profits. This may act as a notable constraint in the growth of the market. Nevertheless, a growing number of clinical trials nearing completion will pave way for commercialization of acne vulgaris treatments, thus opening new revenue streams for market players in the coming years.
Prominent players operating in the acne vulgaris market include Valeant Pharmaceuticals International, Inc., Sol-Gel Technologies Ltd., Sol-Gel Technologies Ltd., Hygeia Therapeutics, Inc., Galderma S.A., Photocure ASA, GlaxoSmithKline plc, Ausio Pharmaceuticals, LLC, and AndroScience Corporation.